Back to search

United Kingdom· GB-APID-7973411000001103

Fuzeon 108mg powder and solvent for solution for injection vials

A enfuvirtide product containing enfuvirtide, registered in United Kingdom by Roche Products Ltd. The same ATC class is registered in 10 of our 19 countries.

ATC J05AX07

Checked against NHS dm+d (United Kingdom) on

Informational only — not a medical device.

SOURCE REGISTER · GBNHS dm+d (United Kingdom)normalisedFuzeon 108mg powder and solvent for s…ATCJ05AX07REGISTER NO.GB-APID-7973411000001…PACKS LISTED2CHECKEDSeptember 13, 2026

Where it is registered

Enfuvirtide is registered in 10 of 19 countries.

Countries holding a registration under ATC J05AX07 (enfuvirtide), each read from that country’s own register.

  • This record: United Kingdom, from NHS dm+d (United Kingdom)
  • 6 of them publish a price we can compare per daily dose

Enfuvirtide · ATC J05AX07

10 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

NHS dm+d (United Kingdom)
Active substance
Enfuvirtide
Manufacturer
Roche Products Ltd
Country
United Kingdom (GB)
ATC code
J05AX07
ATC class
Enfuvirtide
Defined daily dose
0.18 g, P
Reimbursed
Not published by this register
Source register
NHS dm+d (United Kingdom)
Last checked
September 13, 2026

Packs & prices · 2

  • gtin
    5000471006124
  • gtin
    7613326019750

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

2 interactions on record for enfuvirtide.

Graded by severity as the source publishes them — 2 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Enfuvirtide · interactions on record

2 records

  • 2 moderate

Most severe, free to view

  • Darunavir and cobicistatJ05AR14moderate
  • CobicistatV03AX03moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/73ad652e-8855-46f7-863c-5884c900e1ec
GET /v1/drugs/73ad652e-8855-46f7-863c-5884c900e1ec?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "apid": "7973411000001103",
  "desc": "Fuzeon 108mg powder and solvent for solution for injection vials (Roche Products Ltd)",
  "form": "Powder and solvent for solution for injection",
  "vpid": "7973211000001102",
  "source": "dmd",
  "vtm_id": "775766003",
  "strength": "108 mg",
  "substance": "Enfuvirtide",
  "ingredient": "Enfuvirtide",
  "supplier_code": "2085201000001100"
}

See everything about enfuvirtide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.